Glucose News and Research

RSS

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

New fluorescent paper strips make vitamin B12 testing simpler

Measuring vitamin B12 in food usually means bringing the sample to the laboratory. A new fluorescent sensor could help move part of that process onto something much simpler: a paper strip or cotton swab.

1 Oct 2026

New trial tests if diet can reduce bipolar depression symptoms

A clinical trial is set to test whether diet could help reduce depressive symptoms in people with bipolar disorder, comparing a high fat, low carbohydrate diet with standard NHS healthy eating advice.

1 Oct 2026

Mauritius becomes first country to reverse type 2 diabetes epidemic

New research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that the small island nation of Mauritius is the first country in the world to prove it is reversing the type 2 diabetes epidemic using the objective gold standard testing method of the 2-hour oral glucose tolerance test (2 hour OGTT).

1 Oct 2026

Do you really need to fast before a blood test? It depends on the test

The impact of fasting on blood test results is analyte-specific, with most routine tests showing minimal differences, suggesting a need for flexible guidelines.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

Fluorescent sensors could help researchers see diabetes in action

Researchers from the University of Bath have developed fluorescent molecular probes that can detect changes in glucose levels inside living animals, giving scientists new ways of visualizing sugar uptake, studying diabetes, cancer and other metabolic diseases in whole organisms in real time.

1 Oct 2026

Study compares shifting pancreatic cancer burdens in the United States and China

Pancreatic cancer remains one of the deadliest malignancies worldwide, carrying a five-year survival rate of roughly 10% and a heavy toll in disability-adjusted life years.

30 Sep 2026

$5.7 million NIH grant supports research on why lean people develop insulin resistance

A Wayne State University research team was awarded a $5.7 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health focused on discovering the biological mechanisms that may help explain why some lean people develop insulin resistance while some people with obesity remain sensitive to insulin.

29 Sep 2026

Targeting specific nuclear receptor could help preserve aging muscle function

Scientists in the Gerhart-Hines Group pinpoint a molecular cause of muscle aging, and a possible fix. By investigating how muscles adapt to age and disease-related decline, the scientists discovered the involvement of a druggable nuclear receptor, ERRγ, that could be targeted to preserve muscle function.

29 Sep 2026

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

Exercise may reshape your gut microbiome to support recovery

Research reveals how exercise alters gut microbes, influencing recovery and proposing 'intestinal rehabilitation' for those with limited exercise capacity.

29 Sep 2026

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

28 Sep 2026

Exam stress significantly raises blood sugar levels in medical students

Exam stress is associated with significant increases in blood sugar levels in medical students both during exams and the days leading up to them, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

27 Sep 2026

Review highlights how altered metabolism drives kidney cancer growth

Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, is increasingly understood as a malignancy shaped by profound changes in cellular metabolism.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026